Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06686472 · ClinicalTrials.gov registry record · Phase 2
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
A Phase 2 study of Allergic Conjunctivitis, sponsored by Telios Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT06686472 is a Phase 2 study of Allergic Conjunctivitis that is actively recruiting participants, run by Telios Pharma. The registered enrollment target is 66 participants, below the 131-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06686472, a Phase 2 study of Allergic Conjunctivitis, is actively recruiting participants, sponsored by Telios Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TL-925
Study Locations (1)
Tennessee
- Telios Investigative Site - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-10-03 |
| Est. Completion | 2024-12-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06686472
The ClinicalTrials.gov registry entry for NCT06686472 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (50% lower). The listed sponsor is Telios Pharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06686472 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06686472 about?
NCT06686472 is a clinical study titled "Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis". In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using th...
What is the current status of trial NCT06686472?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-10-03. Estimated completion is 2024-12-10.
What conditions does trial NCT06686472 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT06686472?
The interventions under investigation include: Placebo (DRUG), TL-925 (DRUG).
Who is sponsoring clinical trial NCT06686472?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06686472 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
COMPLETED · Phase 2
-
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 2
-
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
COMPLETED · Phase 2
-
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
COMPLETED · Phase 2
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.